Forbes -- Why have the share prices of major pharmaceutical companies been dropping for years? I asked Sanofi-Aventis chief executive Christopher Viehbacher to chat following his company’s full-year earnings call. Here’s an edited transcript of our conversation about layoffs, the future of drug industry research, and why his company is trying to acquire Genzyme.
